Market analysis articles within Nature Reviews Clinical Oncology

Featured

• News & Views | 21 April 2016

  Generic imatinib — impact on frontline and salvage therapy for CML

  Imatinib has revolutionized the treatment of chronic myeloid leukaemia (CML). In 2016, generic imatinib will be introduced into the US market. We analyse the potential impact of this new product on patient care and optimal CML therapy, and comment on the effect that distorted cancer drug pricing in the USA will have on treatment for patients with limited therapeutic options.

  • Larry Gorkin
  •  & Hagop Kantarjian

• News & Views | 13 April 2016

  Addressing conflicts of interest of public speakers at advisory committee meetings

  A study reveals that, from 2009–2014, a considerable percentage of public speakers at Oncologic Drugs Advisory Committee meetings had disclosed or undisclosed financial associations with the drug company seeking product approval. Amid calls for increased public engagement in health care and health-care research, steps must be taken to minimize the conflicts of interests of those who claim to speak for patients and the public.

  • Matthew S. McCoy
  •  & Ezekiel J. Emanuel